Company intelligence / Profile preview
ALX Oncology
South San Francisco, California, United Statesalxoncology.com ↗
- Ownership
- Public · ALXO
- Employees
- ~80
- Development stage
- Phase 2
01
Overview
ALX Oncology’s lead candidate evorpacept has shown strong response rates and durable clinical benefit in HER2-positive gastric cancer patients per updated ASPEN‑06 Phase 2 data. Combination with zanidatamab demonstrated promising anti-tumor activity in advanced breast cancer. The company’s pipeline includes additional trials targeting solid tumors and hematologic malignancies with a focus on combination regimens. Safety profiles have been manageable and consistent with prior experience
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodies (mAbs)antibody-drug conjugates (ADCs)immune stimulating antibody conjugates (ISACs)fusion proteins
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Merck & Co.: Collaboration evaluating evorpacept plus Keytruda for head & neck squamous cell carcinoma.Jazz Pharmaceuticals plc.: Collaboration on zanidatamab combination studies.Quantum Leap Healthcare Collaborative/I-SPY program.MD Anderson Cancer Center.Sanofi.University of Pittsburgh Medical Center.Tallac Therapeutics Inc.
04
Financials
- Market cap
- $255.7M
- Total revenue
- $0
- Enterprise value
- $127.1M
Beyond the preview
Go deeper on ALX Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALX Oncology.